A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard. This research, published in the July issue of The Journal of Nuclear Medicine, lays the foundation for further development of radionuclide therapies targeting CSCs, offering renewed hope for more effective treatment options and improved outcomes for patients.

A team led by researchers at MUSC Hollings Cancer Center developed an artificial intelligence tool that uses natural language processing to identify the original cancer type of patients with brain metastases by analyzing their doctors’ clinical notes. The model outperformed standard diagnostic codes, accurately determining the primary cancer type in over 90% of cases, which can improve research efforts and enable more precise care. The lightweight, scalable tool could streamline cancer care and research by unlocking critical insights buried in electronic health records.

The University of Copenhagen is excited to announce Immortal Dragons as Tier 4 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.

The University of Copenhagen is excited to announce Mitra Bio as Tier 3 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.